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Abstract Intersectin-1s (ITSN-1s) is a general endocytic
protein involved in regulating lung vascular permeability
and endothelial cells (ECs) survival, via MEK/Erk1/2MAPK
signaling. To investigate the in vivo effects of ITSN-1s
deficiency and the resulting ECs apoptosis on pulmonary
vasculature and lung homeostasis, we used an ITSN-1s
knocked-down (KDITSN) mouse generated by repeated
delivery of a specific siRNA targeting ITSN-1 gene (siR-
NAITSN). Biochemical and histological analyses as well as
electron microscopy (EM) revealed that acute KDITSN
[3-days (3d) post-siRNAITSN treatment] inhibited Erk1/
2MAPK pro-survival signaling, causing significant ECs
apoptosis and lung injury; at 10d of KDITSN, caspase-3
activation was at peak, terminal deoxynucleotidyl transfer-
ase dUTP nick-end labeling (TUNEL)-positive ECs showed
3.4-fold increase, the mean linear intercept (MLI) showed
48 % augment and pulmonary microvessel density as
revealed by aquaporin-1 staining (AQP-1) decreased by
30 %, all compared to controls; pulmonary function was
altered. Concomitantly, expression of several growth factors
known to activate Erk1/2MAPK and suppress Bad pro-apop-
totic activity increased. KDITSN altered Smads activity,
downstream of the transforming growth factor beta-receptor-
1 (TbR1), as shown by subcellular fractionation and
immunoblot analyses. Moreover, 24d post-siRNAITSN, sur-
viving ECs became hyper-proliferative and apoptotic-
resistant against ITSN-1s deficiency, as demonstrated by EM
imaging, 5-bromo-deoxyuridine (BrdU) incorporation
and Bad-Ser112/155 phosphorylation, respectively, leading to
increased microvessel density and repair of the injured lungs,
as well as matrix deposition. In sum, ECs endocytic dys-
function and apoptotic death caused by KDITSN contribute to
the initial lung injury and microvascular loss, followed by
endothelial phenotypic changes and microvascular remod-
eling in the remaining murine pulmonary microvascular bed.
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Introduction
Intersectin-1s (ITSN-1s) is a member of ITSN family of
proteins, best-known for its critical role in coordinating
distinct steps in clathrin-coated vesicles (CCVs) and cav-
eolae endocytosis, [1–4]. Due to its endocytic function and
multimodular structure, ITSN-1s links growth factors
receptors and regulatory proteins predominantly localized
in CCVs and caveolae, to signaling networks [1, 2, 5, 6].
ITSN-1s activates Ras, via its association with mSOS, a
GEF for Ras, leading to downstream Erk1/2MAPK signaling
activity [7]. Previous studies indicated that downregulation
of ITSN-1s via siRNA inhibits Erk1/2MAPK and its direct
activator MEK, leading to mitochondrial apoptosis of
cultured human lung microvascular ECs [8]. The findings
are consistent with pro-survival signaling orchestrated by
ITSN-1s via mSOS/Ras/Erk1/2MAPK pathway, known to
play a pivotal role in cell survival, proliferation and
vascular remodeling, [9–11].
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ECs dysfunction and apoptotic death are common events
in many pathological conditions such as sepsis, inflam-
matory syndromes, atherosclerosis, and pulmonary arterial
hypertension (PAH), [12]. Recent studies showed that
increased pulmonary ECs apoptosis caused by loss-
of-function mutations in bone morphogenetic protein
receptor-2 (BMPR2) may represent a possible initiating
mechanism in PAH, [13]. Moreover, studies using chron-
ically hypoxic SU5416-treated rats indicated that increased
apoptosis of ECs created conditions favoring the emer-
gence of apoptosis-resistant cells and that blockade of ECs
growth factors receptors worsen the pathological vascular
remodeling [14].
ITSN-1s is one of the recently identified substrates for the
cytotoxic protease granzyme B (GrB), [15], raising the
possibility that during inflammatory processes, major path-
ogenic components of pulmonary vascular remodeling, [16],
ITSN-1s can be cleaved and thus, expression of full-length
protein reduced. Recently, we have shown that ITSN-1s
deficiency is relevant to the pro-inflammatory ECs dys-
function induced by lipopolysaccharide; the decrease in
ITSN-1s mRNA and protein expression were countered by
Bcl-XL and survivin upregulation, as well as Bim down-
regulation, events thought to protect ECs from impending
apoptosis [17]. Little is known about ITSN-1s deficiency and
its implications in human lung diseases, since no studies have
examined the consequences of KDITSN and the subsequent
ECs dysfunction and apoptotic death in vivo. With the recent
introduction of siRNA, the silencing of genes involved in
pathologic mechanisms is carried out extensively in vitro,
but more limited in vivo, due to either inefficient KD or
adverse effects, such as immune responses, toxicity or off-
target effects [18]. Recently, using cationic liposomes/
siRNAITSN complexes delivered retro-orbitally into mice we
knocked down ITSN-1s protein and mRNA levels in mouse
lungs for 24 consecutive days [19]. The amounts of
siRNAITSN injected (100 lg siRNA/mouse) were signifi-
cantly lower compared to previously reported data [20], and
sufficient for efficacy with no detectable adverse effects.
Using this KDITSN mouse model, we have shown that lung
ECs deficient of ITSN-1s, while impaired in caveolae and
CCVs endocytosis, show up-regulation of alternative endo-
cytic pathways (i.e. enlarged endocytic structures, mem-
branous rings and tubules, etc.,) to compensate for deficient
vesicular trafficking [19]. It is well-known that endocytosis
and vesicular trafficking have significant impact on growth
factors receptors signaling/activity and their associated
proteins and downstream targets [21–23]. Endocytic dys-
function and altered intracellular trafficking and signaling of
cell surface receptors such as TbRs, BMPR2 and tyrosine
kinase receptors [i.e. vascular endothelial growth factor
receptor (VEGF-R), platelet-derived growth factor receptor,
(PDGF-R), insulin receptor (IR) etc.] have been implicated
in the pathogenesis of PAH, emphysema and chronic
obstructive pulmonary disease [24–27], pointing to impli-
cations of disrupted intracellular membrane trafficking in the
pathobiology of vascular remodeling. However, studies on
the potential involvement of ECs dysfunctional endocytic
membrane traffic and the consequences on growth fac-
tor(s) receptors signaling in the pathology of lung micro-
vascular remodeling are limited. Thus, the aim of this study
was to elucidate the in vivo effects of ECs apoptosis and
impaired endocytic membrane trafficking caused by ITSN-
1s deficiency on mouse lung vasculature and lung homeo-
stasis, using the lung-specific KDITSN mouse model we
generated [19]. Here, we show that specific downregulation
of ITSN-1s expression in mouse lungs causes ECs death and
lung injury, followed by endothelial phenotypic changes
toward hyper-proliferation and apoptosis-resistance, leading
to lung repair and microvascular remodeling in the remain-
ing pulmonary microvascular bed. Overall these findings
established an important role of ITSN-1s in the ECs function
and maintenance of lung homeostasis, while illustrating the
effectiveness of siRNA in vivo.
Materials and methods
Delivery of siRNAITSN to mouse lungs
Young mice (6–8 weeks), as well older mice (24 weeks)
were used in the studies. A specific ITSN-1s siRNA sequence
(100 lg siRNA/mouse) targeting ITSN-1 gene was deliv-
ered via cationic liposomes, by retro-orbital injection, into
mouse lungs as in [19, 28]. Pilot studies we performed to
determine the siRNAITSN amount needed for efficient
KDITSN without structural alteration of mouse organs, lung
included. Chronic inhibition of ITSN-1s, was achieved by
repeated siRNAITSN/liposomes delivery, every 72 h, for 24d
as in [19]. Mice were sacrificed at 3, 10 15 and 24d; Three to
four mice per experimental condition [controls (wt-mice,
vehicle- and non-specific siRNA-treated mice) and siR-
NAITSN-treated mice] were used; all these experiments were
repeated three times. No mouse mortality was recorded
during the 24d of this experimental approach. All animal
studies were performed in accordance with the guidelines of
the University Institutional Animal Care and Use Commit-
tee. All surgeries were performed under anesthesia using i.p.
delivery of 1 ml/kg body weight of ketamine hydrochloride/
xylazine hydrochloride solution, (Sigma, St. Louis, MO).
Protein extraction
Lungs free of blood by in situ perfusion (1.5 ml/min warm
Hank’s solution) were homogenized in 150 mM NaCl,
50 mM Tris, pH 8.0 and protease inhibitors; total lysates
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were prepared by adding NP-40, to a final concentration of
1.0 %, for 2 h, at 4 C. The ensuing lysates were clarified
by centrifugation in a Beckman ultracentrifuge with a
TLA-55 rotor, at 45,000 rpm, for 45 min, at 4 C. Protein
concentration was determined by the microBCA, (Pierce
Biotechnology, Rockford, IL), with a bovine serum albu-
min (BSA) standard.
Subcellular fractionation
Nuclear and cytosolic fractions of mouse lungs were pre-
pared as in [29]. Lung tissue, free of blood by in situ
perfusion of Hank’s solution, was washed twice with PBS
and then transferred to hypotonic buffer (250 mM sucrose,
50 mM Tris–HCl, pH 7.4, 5 mM MgCl2, 1 mM DTT, and
1 mM phenylmethyl sulfonyl fluoride) for 30 min to allow
swelling. The tissue was then Dounce-homogenized
(20–30 strokes) with a tight-fitting pestle. The homogenate
was centrifuged in a refrigerated Beckman benchtop cen-
trifuge at 8009g for 15 min; the postnuclear supernatant
served as cytosol, while the pellet, which contains the
nuclei, was resuspended in a lysis buffer and centrifuged
again as above. The supernatant served as the ‘‘nuclear’’
fraction and further used for assessing Smads nuclear
translocation.
Western blot and densitometry
Total protein (70 lg/lane) of mouse lung lysates was
subjected to 4–20 % SDS PAGE, transferred to nitrocel-
lulose membranes, followed by Western blot as in [30].
The antibodies (Abs)—AQP-1, Smad4/7 pAbs, histone-3,
VEGF-A, a dual BMP-2/4 mAbs and phospho-Smad2 pAb,
(Santa Cruz Biotechnology, Santa Cruz, CA), Bad and
phospho-Bad pAbs, BrdU mAb, and phospho-Erk1/2 mAb,
Erk1/2, TGFb Smad1, phospho-Smad1/5/8, caspase-3
pAbs (Cell Signaling, Danvers, MA) phospho-Smad3 pAb
(Abcam, Cambridge, MA) were used as recommended by
the manufacturers, at dilutions established in preliminary
experiments. ITSN-1s mAb (BD Biosciences, San Jose,
CA) was used throughout the study to evaluate the efficient
KDITSN in mouse lung tissue. The bands of immunoreac-
tivity were visualized using appropriate horseradish per-
oxidase-conjugated Abs (eBioscience, San Diego, CA) and
enhanced chemiluminescent substrate (Pierce, Rockford,
IL). HyBlot CL films were subjected to densitometric
analysis using ImageJ1.37v software.
Lung histology
Controls and siRNAITSN-treated mouse lungs were inflated
with 1 % low-melting point agarose in 10 % formalin at a
constant pressure of 25 cm H2O, allowing for homogenous
expansion of lung parenchyma, and then fixed in 10 %
paraformaldehyde for 48 h and paraffin-embedded [31,
32]. Thin sections (6 lm), were stained with hematoxylin/
eosin (H&E) for lung tissue histological evaluation. Images
(5 per lung section, 3 sections per mouse, 3–4 mice per
group) were acquired with a 10 9 lens and used for mor-
phological assessment. MLI, a measure of interalveolar
wall distance was evaluated on micrographs (35 micro-
graphs randomly selected/specimen/3 different experi-
ments) as in [31]. Briefly, the length of a line drawn across
the lung section was divided by the total number of inter-
cepts encountered in 100 lines per each section analyzed.
Measurement of lung mechanics
Assessment of pulmonary lung function in controls and
liposome/siRNAITSN-treated mice was performed using the
Flexivent system (Scireq, Montreal, Canada) as in [33, 34].
Briefly, mice were anesthetized with inhaled isoflurane in
oxygen and orotracheally intubated with a 20-gauge
intravenous cannula under direct vision. Isoflurane anes-
thesia was maintained throughout the measurements, and
the mice were hyperventilated to eliminate spontaneous
ventilation. Before testing each mouse, tube calibration
was performed to remove the mechanical impedance of the
tracheal cannula. Then, starting at functional residual
capacity, the Flexivent was programmed to deliver seven
inspiratory volume steps, for a total volume of 1 ml, fol-
lowed by seven expiratory steps, pausing at each step for at
least 1 s. Using this approach we evaluated the lung
compliance (CL) and resistance (RL) as well as the inspi-
ratory capacity (IC). Statistical analysis was performed
with SigmaStat software using one-way ANOVA testing
method (n = 4/each time point investigated). Statistical
difference was accepted at P \ 0.05. All data are presented
as mean ± SEM.
Lectin staining
Lectin staining was performed using biotinylated Griffonia
Symplicifolia-1 (GS-1; Sigma) which binds specifically to
a-galactosyl residues from microvascular endothelium [35].
After dewaxing and rehydration in PBS, the sections were
blocked for unspecific binding with 1 % BSA in PBS, for
30 min. GS-1 (50 lg/ml) was applied for 1 h, at RT, in a
humidified chamber. After washing, sections were incubated
with NeutrAvidin dyelight (Sigma) for 30 min, and mounted
with Prolong Antifade reagent (Molecular Probes).
Aquaporin-1 (AQP-1) staining and morphometry
Deparaffinized and hydrated tissue sections were incubated
for 15 min with 1.5 % H2O2 for blocking the endogenous
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peroxidase activity, followed by 1 h in 10 mM sodium cit-
rate, pH 6.0, at 65 C for antigen unmasking, as in [36].
Incubation with AQP-1 Ab for 30 min, at RT was followed
by biotinylated universal Ab diluted in 2 % mouse serum and
Vectastain ABC reagent (Vector Labs.) for 30 min, each.
NovaRed substrate (Vector Labs.) was used for developing
the red color. The number of microvessels labeled by AQP-1
was estimated by superimposing a rectangular grid over the
sections and the microvessels included within the boundaries
of each rectangle, were counted. The criterion used for
identifying and counting microvessels was a circular/ellip-
tical contour (\9 lm diameter) labeled by the AQP-1 Ab.
When a capillary placed on the grid lines, it was considered
only one time. Images (5 per lung section, 3 sections per
mouse, and 3–4 mice per group) were acquired with a
63 9 lens and used for morphological assessment. A mini-
mum of 25 randomly chosen power fields per section form
controls and ITSN-1s deficient mice were measured at a final
magnification of 3009.
Apoptosis and cell proliferation assays
TUNEL was carried out as per manufacturer’s instructions,
(Roche, Indianapolis, IN). Paraffin-embedded sections from
controls and siRNAITSN-treated mouse lungs were depa-
raffinized, washed in PBS and treated with proteinase K, for
20 min at RT. The TUNEL mixture was applied for 60 min
in a humidified atmosphere at 37 C, in the dark. After
washing, the sections were mounted using Prolong Antifade
reagent. Lung sections incubated with TUNEL solution in
the absence of TUNEL enzyme solution were used as neg-
ative control. TUNEL-positive ECs were identified by
fluorescence microscopy using an excitation wavelength of
488 nm. Lung autofluorescence was reduced by incubation
of lung sections, for 5 min with sulphorhodamin solution.
BrdU incorporation
Mouse lungs ECs were labeled with BrdU solution (Roche,
Indianapolis, IN) by intraperitoneal injection every 24 h,
for two consecutive days. Paraffin-embedded sections were
dewaxed and rehydrated in PBS for 10 min. Trypsin
solution was applied for 5 min. The sections were dena-
tured in 4 M HCl for 15 min and washed again in PBS.
Next, each preparation was incubated with anti-BrdU/FITC
Ab, for 45 min, at 37 C in a humid chamber. After the last
washing in PBS, the slides were mounted as above.
Quantification of BrdU- and TUNEL-positive nuclei was
performed on medium-sized (50 C diameter B 100 lm)
blood vessels. Using Zeiss Axiovision software we measured
the diameter of the vessels by drawing an imaginary line
perpendicular to the direction of the largest profile dimension
which was then averaged with the value at its greatest width.
A minimum of 25 vessels per section (3 sections per mouse,
3–4 mice per group) were used for counting the number of
TUNEL- and BrdU-positive ECs nuclei. Data was normal-
ized per 25 vessels.
BrdU-positive ECs were counted on 25 alveolar profiles
in controls and siRNAITSN-treated mouse lung sections.
For treated specimens, only alveolar profiles with more
than one ECs TUNEL-positive were considered on ran-
domly chosen middle power fields.
Collagen staining
Paraffin-embedded mouse lung sections were deparaffinized
and hydrated in distilled water, stained in hematoxilyn and
then subjected to Picrosirius Red (Polysciences) staining as
instructed by the manufacturer. Finally, sections were dehy-
drated, cleared in xylene, and mounted with Paramount
(Fischer Scientific). Picrosirius Red staining was imaged
using a Zeiss Axio Observer Z1 Motorized Inverted Micro-
scope; morphometry was performed using ImageJ1.37v soft-
ware. Areas of interest were defined using 20–25 high power
microscopic fields/mouse/experimental condition. The per
area density of binding/staining was obtained by averaging the
percentage values obtained for each area of interest analyzed.
Statistical analysis
Statistical analysis was performed using Student’s two-
tailed, unpaired t test for comparison between groups, for
collagen staining and ANOVA testing for all other lung
morphometry. Data are reported as mean ± SEM, Statis-
tical significance was accepted at P \ 0.05.
EM
Mouse lungs, free of blood, were fixed by perfusion with
3 % paraformaldehyde and 1.5 % glutaraldehyde in 0.1 M
Na cacodylate buffer, pH 7.3 [37]. Excised tissue was fixed
in the same fixative mixture for one additional hour, at RT,
post-fixed in Palade’s 1 % OsO4 on ice, and then stained
with Kellenberger uranyl acetate. Selected specimens were
dehydrated in graded ethanol and embedded in Epon812.
Thin sections cut from blocks were mounted on nickel
grids, stained with 2 % uranyl acetate and lead citrate, and
finally examined and micrographed in a Joel 1220 TEM.
Results
Specific KDITSN in mouse lungs
ITSN-1s protein and mRNA levels were monitored at
several time points after siRNAITSN delivery by Western
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blot and RT- and qPCR as in [19]. ITSN-1s protein and
mRNA levels in siRNAITSN-treated mouse lungs were
about 75 % lower by reference to controls. Delivery of
empty-liposomes or liposomes containing the non-specific
siRNA did not affect the levels of ITSN-1s protein or
mRNA, compared to controls. Comparable ITSN-1s
downregulation, with the same timeline as in the lung, was
detected in the brain, while in the heart, kidneys and liver
was less efficient (not shown). This KDITSN murine model
generated by liposome delivery of the siRNAITSN was used
to further confirm in vivo that ITSN-1s deficiency induces
ECs apoptosis in the pulmonary vasculature while affecting
lung homeostasis.
Acute KDITSN causes ECs apoptosis, microvessel loss
and mouse lung injury
To investigate the effects of ITSN-1s deficiency on ECs
apoptosis in the lungs of the KDITSN mouse we applied
TUNEL reaction on paraffin-embedded sections of
siRNAITSN-treated mice, 72 h post-siRNA delivery. TUN-
EL-positive ECs, identified as elongated fluorescent puncta
lining the blood vessel profiles were frequently associated
with the perimeter of large vessels, (Fig. 1A, a1, a2), as well
as medium-sized vessels, (Fig. 1B, b4). Morphometric
analyses indicated an average of 4.6 TUNEL-positive ECs/
mid-sized vessel profile in KDITSN mouse lung specimens,
while in control specimens, wild-type mice, (Fig. 1B, b1),
vehicle-treated (b2), or non-specific siRNA-treated mice
(b3), their number decreased to 1.92 TUNEL-positive ECs/
mid-sized vessel profile, 2.4-fold less compared to KDITSN
specimens (Fig. 1C; Table 1). For specific evaluation of
apoptotic ECs death within alveolar wall, TUNEL reaction
(Fig. 1B, b5) was complemented by co-immunostaining for
the generally accepted ECs marker, CD31 (CD31 Ab; Santa
Cruz Biotechnology, Santa Cruz, CA; Fig. 1B, b6), as in
[38]. Frequently, TUNEL-positive nuclei co-localized with
cell membranes labeled by CD31/AlexaFluor594 Ab
(Fig. 1B, b7, b8). TUNEL-positive cells were detected with
a lesser frequency among alveolar epithelial cells and other
resident cells of the lung (Fig. 1B, b7, arrows). Often, septal
walls remnants displayed apoptotic ECs (Fig. 1B, b8,
arrowheads) and epithelial cells (Fig. 1B, b8, open arrow) at
their tip. TUNEL-positive lung cells were rare under control
conditions (not shown).
Given the size of lung capillaries (\7–8 lm diameter),
the thickness of the cellular and interstitial barrier in the
thinnest regions of the alveolar septum (300–600 nm) [39],
as well as the limited resolution of fluorescence micros-
copy in this range, accurate quantification of apoptotic ECs
in lung microvessels was difficult. To obviate this limita-
tion we monitored the changes in lung microvessels during
acute KDITSN by AQP-1 immunostaining. AQP-1 water
channels are expressed on apical and basolateral mem-
branes of mammalian lung microvascular ECs and only
occasionally in alveolar pneumocytes (type II), which are
morphologically different from ECs and thus, not likely to
interfere with identification of microvessels [40]. Numer-
ous circular/elliptical profiles strongly labeled by AQP-1
Ab were detected in the lung microvasculature of wild-type
mice (Fig. 2A, a1), contrasting with the limited number of
similar AQP-1 outlined contours at 3d of siRNAITSN
(Fig. 2A, a2). Note the reduced thickness of the septal wall,
the decreased number of microvessels and the more diffuse
AQP-1 staining in siRNAITSN-treated lungs, most likely
due to increased number of apoptotic events at this level.
Quantitative measurements indicated that the mean number
of lung microvessels per 30,000 lm2 surface area varies
from 38.8 ± 4 (controls) to 28.81 ± 2.4 (3d). Omitting the
primary Ab or using an isotype-matched IgG (Fig. 2A, a3,
a4) show no ECs staining; a light-reddish background
caused by the NovaRed substrate revealed thinner alveolar
walls and evident signs of damage under siRNAITSN con-
ditions (Fig. 2A, a4).
Histological evaluation revealed that the excessive ECs
apoptosis caused loss of septal tissue, air space enlarge-
ment and alveolar destruction in KDITSN specimens
(Fig. 3A, a4, asterisks). No detectable modifications of
pulmonary parenchyma were present in the histology of
wild-type, vehicle-, or control siRNA-treated mice
(Fig. 3A, a1, a2, a3). The MLI, as a measure of the alveolar
size was used to quantify the enlargement of the airspace,
as in [31]. At 72 h of KDITSN, MLI was 35 % increased
compared to controls (Fig. 3B). Since ITSN-1s protein
expression began to recover at 168 h post-siRNAITSN
treatment [19], we also examined the mouse lung histology
3d later (240 h post-siRNAITSN). Less alveolar destruction
and limited enlargement of air spaces (Fig. 3A, a5) as well
as the decrease in MLI values from 35 to 19.8 % compared
to controls (Fig. 3B), suggested that restoring ITSN-1s
protein levels re-established pro-survival signaling leading
to partial recovery of lung histology. No differences in the
extent of ECs apoptosis and lung injury were observed in
older mice (24 weeks) versus young mice (6–8 weeks).
Key morphological features of ECs apoptosis and lung
injury induced by KDITSN were also identified by detailed
EM surveys of the mouse lungs deficient of ITSN-1s.
Frequently, ECs with increased number of mitochondrial
units, many of them with abnormal morphology, Golgi
apparatus with swollen and unstacked cisternae (Fig. 3C,
c3), as well as ECs nuclei displaying evident signs of
chromatin condensation (Fig. 3C, c4), were noticed in
KDITSN mouse specimens. For comparison, Fig. 3C, c1, c2
illustrate fragments of wild-type mouse lungs ECs with
normal mitochondria, well-organized Golgi, as well as a
healthy nucleus. Caveolae, the main vesicular carriers of
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ECs are numerous and frequently found open to the lumen
or apparently free in the cytosol (Fig. 3C, c.1.1). We have
often observed in the lungs of KDITSN mice ECs displaying
finger-like protrusions in the lumen of the blood vessels
(Fig. 3C, c5, arrowheads), evidence of a dysfunctional































a1 Pulmonary vein a2 Pulmonary artery
B
b8
b1 b2 b3 b4
b5 b6 b7
62 Apoptosis (2013) 18:57–76
123
membraneous protrusions are very dynamic structures,
likely involved in the release of circulating membrane
particles, involved in the maintenance and preservation of
cellular homeostasis and in promoting defense mechanisms
[41, 42]. In addition some of these protrusions are physi-
ologically relevant since they may function in pinocytosis
to compensate for deficient endocytic membrane traffic via
caveolae and CCVs [19]. Significantly, as a consequence of
endothelial injury caused by ITSN-1s deficiency, the per-
meability of the alveolo-capillary unit was affected, leak-
age of the protein-rich fluid from the vascular to the
interstitial space occurred, causing dilation of the intersti-
tial space at the level of the alveolar septa (Fig. 3C, c4, c5).
Overall, we noticed that the lung injury caused by KDITSN
was patchy, mainly localized at the level of the alveolo-
capillary units, centered on small vessels (capillaries, post-
capillary venules) and around some mid-sized vessels
(collecting and muscular venules). Most likely, this patchy
distribution reflects the efficient delivery of the siRNAITSN
and thus, downregulation of ITSN-1s. Altogether, the
observations indicated that ITSN-1s expression is impor-
tant for ECs function and survival and that ECs death is an
important feature of lung injury in this mouse model.
Time course of ECs apoptosis in mouse lungs
with chronic KDITSN
The time course of ECs apoptosis in mouse lungs with
chronic KDITSN (24d post-siRNAITSN), was evaluated by
activated caspase-3 immunoreactivity and TUNEL reaction.
Western blot applied on total mouse lung lysates revealed
cleaved caspase-3 at 3d post-siRNAITSN delivery (Fig. 4A),
with a peak at 10d followed by a gradual decrease to control
levels, at 24d. No changes were detected in the total caspase-
3 (Fig. 4A). Given the high endothelial content of the lung
tissue [30, 39, 43], the lung lysates are a good starting
material for biochemical investigations and thus, the findings
highly significant for ECs of the lung.
Densitometric analysis indicated more than 3-fold
increase in cleaved caspase-3 at 10d, compared to
untreated mice (Fig. 4B). TUNEL (Fig. 4C, c1), followed
by CD31 Ab staining for specific detection of ECs within
the alveolar wall, (Fig. 4C, c2) also revealed increased
number of apoptotic ECs nuclei at 10d (Fig. 4C, c3,
arrows) compared to 3d KDITSN. We have also detected
TUNEL-positive alveolar epithelial cells (Fig. 4C, c3, open
arrows). Their apoptotic death can be due to both, (i) the
excessive death of ECs and subsequent collapse of the
capillary bed, essential for the maintenance of alveolar
septa and (ii) a direct effect of KDITSN at this level. When
the extent of ECs apoptosis in medium-sized vessels was
evaluated by TUNEL, morphometric analysis indicated
that the number of apoptotic ECs reached the highest val-
ues at 10d of KDITSN, (Fig. 4D, Table 1), consistent with
caspases-3 activation. Moreover, AQP-1 Ab staining and
morphometric analysis indicated a further loss of pul-
monary microvessels; at 10d, the mean number of lung
microvessels per examined area reached the lowest value
of 25.6 ± 4, (Table 1). Even with significant apoptosis, no
mortality occurred among mice with KDITSN for 24 con-
secutive days. Despite continuous and efficient KDITSN, at
24d, the number of apoptotic ECs in medium-sized vessels
decreased by 50 % compared to controls and by 85 %
compared to KDITSN, at 10d (Table 1), while in the alve-
olar wall they were detected only occasionally. All
Table 1 Morphometric analysis of ECs apoptosis, proliferation and microvessel density in the lungs of KDITSN mouse. The number of lung
microvessels labeled by AQP-1 and GS-1 lectin was normalized per 30,000 lm2 surface area
Label/time point Ctrl. 72 h 10d 24d
TUNEL ? ECs/25 medium-sized vessels 48.0 ± 2.4 115 ± 2.9 165 ± 2.8 25 ± 2.0
AQP-1 microvessels, Ø \ 9 lm 38.8 ± 4.0 28.81 ± 2.4 25.6 ± 4.0 ND
BrdU ? ECs/25 medium-sized vessels 83.0 ± 5.0 ND 154 ± 3.8 173 ± 5.6
BrdU (1.5 9 102 lm alveolar wall length) 4.4 ± 1.0 ND 8.3 ± 1.5 9.4 ± 1.8
GS-1 lectin(microvessels, Ø \ 20 lm) 365 ± 9.0 270 ± 4.5 ND 443 ± 7.1
Fig. 1 Acute inhibition (72 h post-siRNAITSN) of ITSN-1s expres-
sion induces apoptosis in mouse lungs. A, B TUNEL demonstrates an
increase in apoptotic ECs death in the lungs of mice with acute ITSN-
1s inhibition (a1, a2, b4), by reference to controls, wild-type mice
(b1), vehicle-injected mice (b2) or non-specific siRNA-treated mice
(b3). TUNEL-positive ECs (arrows) were detected in large vessels—
segments from a pulmonary vein (a1) and a pulmonary artery (a2) are
shown, as well as in medium-sized (50–100 lm diameter) vessels
(b4). Bars 30 lm (a1, a2), 20 lm (b1, b2). Lung sections of KDITSN
mice (3d) were stained with TUNEL (b5) and CD31 Ab (b6) to
evaluate the presence of apoptotic ECs within the microvessels of the
alveolar septum (b7). Arrows in b7, indicate TUNEL-positive alveolar
epithelial cells. The tips of damaged septal walls display TUNEL-
positive ECs nuclei (b8, arrowheads) and alveolar epithelial cells
nuclei (b8, open arrow) Bars 20 lm (b3–b7); 10 lm (b8). C Quan-
tification of TUNEL-positive ECs in medium-sized vessels
(50–100 lm) of controls and siRNAITSN-treated mice lungs;
*P \ 0.05. Results are representative for three different experiments,
with 3–4 mice/experimental condition
b
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together, these observations suggested that extensive ECs
death, recorded at 10d of KDITSN, may stimulate ECs
hyper-proliferation and perhaps, apoptosis-resistance.
Chronic KDITSN mouse lungs show phenotypically-
altered ECs
The scarce ECs apoptosis detected in chronic KDITSN mice
and the lack of physical evidence of disease in these mice
dictated the assessment for compensatory ECs prolifera-
tion. We quantified proliferating ECs by BrdU incorpora-
tion as described under Methods. Paraffin-embedded lung
sections of BrdU-injected mice, controls (wild-type,
empty-liposomes and siRNActrl/liposomes) as well as
siRNAITSN-treated mice were incubated with anti-BrdU
Ab, followed by CD31Ab, for specific detection of ECs
A a1 a2









Control 72 h, ITSN-1s siRNA
Fig. 2 Acute inhibition (72 h post-siRNAITSN) of ITSN-1s expres-
sion causes lung microvessel loss. A Micrographs of AQP-1staining
of lung sections from controls (a1) and KDITSN mice, 3d, (a2), show
decreased number of AQP-1 labeled microvessels (diameter or
transverse diameter, respectively \9 lm) in siRNAITSN relative to
control specimens. Arrows indicate microvessel profiles whose
boundaries are labeled by AQP-1 Ab. Isotype-matched IgG staining
of mouse lung sections of wt- (a3) and KDITSN mice (a4) produced no
ECs staining. The NovaRed substrate produced a light-reddish
background. Bars 10 lm (a1, a2), 15 lm (a3, a4). Results are
representative for three different experiments, with 3–4 mice/exper-
imental condition
Fig. 3 KDITSN induces lung injury. A Representative histo-pathology
of mouse lungs from wild-type control (a1), vehicle (a2), siRNActrl
(a3), siRNAITSN (1 single dose) treated mice, at 72 h (a4) and 240 h
(a5) post-siRNAITSN treatment. H&E staining of paraffin-embedded
tissue shows expanded airway spaces (a4, asterisks) in mouse lungs
with acute inhibition of ITSN-1s. Bar 60 lm. B MLI of control and
siRNAITSN-treated mice. All results are representative for at least 3
independent experiments; 30 random power fields were counted from
each time point, (n = 3 mice/group; *P \ 0.05). C EM morphological
analysis of KDITSN mouse lungs, 72 h post-siRNAITSN. Fragments of
ECs of wild-type mice show normal mitochondria (m), (a1, arrows),
flattened Golgi cisternae, situated in close apposition as stacks (circled
area), caveolar profiles open to the lumen or apparently free in the
cytosol, (inset a.1.1) and a healthy nucleus (a2). ECs of KDITSN show
increased number of mitochondrial units (m; a3, a5), swollen Golgi
apparatus (a3, circled area) and chromatin condensation (a4). Frag-
ment of ECs showing numerous finger-like projections (a5, arrow-
heads). Note also the enlarged perivascular space (pvs) and the thick
alveolar septum in the KDITSN by comparison to control (inset, c5.1).
Bars 100 nm (c1.1); 200 nm (a1–a5, c5.1). Results are representative
for 3 different experiments, with 3 mice/experimental condition
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followed by the appropriate fluorophore-conjugated
reporters. Acute KDITSN revealed only sporadic BrdU-
positive ECs (not shown). However, at 10d of KDITSN the
BrdU-positive ECs were more numerous (Fig. 5A, a1, a3,
arrows) and became greater at 24d of KDITSN, (a4–a9,
arrows). Epithelial alveolar cells showed a similar prolif-
eration pattern; BrdU-labeled nuclei were often detected in
lung alveoli at 24d of KDITSN, (Fig. 5A, a8, a9, arrow-
heads). Morphometric analyses applied on medium-sized
vessels showed a 1.85-fold increase in BrdU-labeled ECs
nuclei at 10d of KDITSN, when apoptosis was at peak and a
2.1-fold increase at 24d, compared to controls (Table 1).
The proliferating, BrdU-positive, ECs within alveolar
microvessels, normalized per 1.5 9 102 lm of alveolar
wall length, increased from 4.4 ± 1.0, in controls, to
8.3 ± 1.5, at 10d to 9.4 ± 1.8 at 24d (Table 1).
The increased cell proliferation in chronic KDITSN
strongly indicated that the survival signaling was restored.
Therefore, we evaluated the Erk1/2MAPK activation, known
to be affected by ITSN-1s deficiency [8]. Erk1/2MAPK
phosphorylation was barely detected at 72 h post-siRNAITSN
delivery (Fig. 5B); however, by 10d, Erk1/2 activation
increased about 50 % over the baseline (Fig. 5B, line a),
reached a peak at 15d and was still above controls, at 24d of
KDITSN; no changes in total Erk1/2
MAPK were detected.
Control experiments using mice injected with siRNActrl/
liposomes complexes (Fig. 5B, line b) and liposomes only































































wt-ctrl 3dveh 10d 15d 24d
ITSN-1s siRNA
Fig. 4 Chronic inhibition of ITSN-1s in mouse lung endothelium
causes a peak in caspases-3 activation and significant ECs death at
10d of KDITSN. A Western blot analyses of lung lysates (70 lg
proteins/lane) of siRNAITSN and control mice show augmented
immunoreactivity for cleaved caspases-3 at 10d of KDITSN, while
total caspase-3 expression is unchanged. b Densitometric analysis of
representative HyBlot CL films indicates more than 3-fold increase in
cleaved caspase-3 immunoreactivity at 10d of KDITSN, by reference
to untreated mice. Densitometric values ± SEM are representative
for three independent experiments. c Lung sections of KDITSN mice
(10d) were stained with TUNEL (c1) and CD31 Ab/AlexaFluor594
(c2) to evaluate the presence of apoptotic ECs within the microvessels
of the alveolar wall. The merged image revealed numerous apoptotic
ECs (c3, arrows) as well as epithelial alveolar cells (c3, open arrows).
Bar 20 lm. d Quantification of TUNEL-positive ECs in medium-
sized vessels (50–100 lm) of controls and siRNAITSN-treated mice
lungs; P \ 0.05 for all time points, relative to controls. Results are
representative for 3 different experiments, with 3–4 mice/experimen-
tal condition
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changes in Erk1/2 phosphorylation compared to the baseline
(Fig. 5B, line a). Since Erk1/2MAPK activation can be related
to increased expression of growth factors [44], and since the
Ras/Erk1/2MAPK is a major signaling pathway downstream
of TbR1 [45], we next evaluated the expression of TGF a
multi-functional cytokine shown to be involved in ECs
proliferation, survival and maintenance of vascular integrity
[46]. A modest boost of mature TGFb at 72–20 % increase
compared to control, and a further a 3-fold increase at 10d
post-siRNAITSN treatment, when apoptosis was at peak
(Fig. 5C, D), suggested that TGFb may account for Erk1/
2MAPK activation in KDITSN mice. A gradual decrease to
under baseline levels at 24d, were consistent with the stim-
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Significant immunoreactivity for the TGFb homodimeric
pro-protein (Mr 74-kDa), was detected at all time points,
(Fig. 5C). A dual BMP-2/4 Ab, revealed that the level of
mature BMP-2/4, two TGFb family members able to initiate
ECs proliferation [47–49], was increased by 2.2-fold at 15d
and 1.7-fold at 24d KDITSN, compared to controls (Fig. 5C,
D). Finally, VEGF-A, a multifunctional cytokine that stim-
ulates ECs to survive, proliferate and alter the pattern of their
gene expression [50], and whose downstream signaling
includes Erk1/2MAPK activation, paralleled BMP-2/4
(Fig. 5C, D). One of likely targets of phosphorylation, by
growth factors-activated Erk1/2MAPK is the Bcl-2 family Bad
[51, 52]. Bad phosphorylation causes inactivation of its pro-
apoptotic properties by blocking the interaction with Bcl-XL,
[44, 51]. Immunoblotting using site-specific phospho Abs
indicated Bad phosphorylation at, Ser112 and Ser155,
(Fig. 5E); No phosphorylation of Bad-Ser136, a preferred
substrate for PI3K/Akt [53], was identified. PI3K/Akt acti-
vation, a downstream target of VEGF signaling [52], was not
detected in this cellular context (not shown). We concluded
that these multi-functional growth factors may act syner-
gistically to re-establish pro-survival signaling and engage
anti-apoptotic pathways, shifting the ECs phenotype
toward hyper-proliferation and apoptosis-resistance against
ITSN-1s deficiency.
Chronic KDITSN induces alveolar and vascular
remodeling
H&E staining of mouse lung sections indicated that the
alveolar destruction caused by KDITSN progresses up to
10d of the siRNAITSN treatment. The lung injury initiated
at 3d of KDITSN is more prominent after 10d of ITSN-1s
inhibition (Fig. 6A, a2). Surprisingly, at 24d of KDITSN,
the damage is greatly diminished (Fig. 6A, a3); lung
morphology, as assessed by H&E staining is similar to
controls (Fig. 6A, a1). Apparently, prolonged KDITSN is
followed by endothelial repair and pulmonary architecture
remodeling. The lung morphology displays smaller alveoli,
densely packed in configuration and few remained signs of
tissue destruction. After 10d of KDITSN, the MLI showed a
48 % increase compared to controls and additional 13 %
compared to the MLI values for lung specimens, 3d post-
siRNAITSN delivery (Fig. 6B). At 24d of KDITSN, however,
despite the extensive apoptotic death and continuous
KDITSN, the MLI values were reversed to control levels,
consistent with the alveolar remodeling process. In contrast
to other vascular remodeling murine models, pulmonary
inflammatory infiltrates or vascular enlargements were not
detected in KDITSN mouse lungs.
Lung cells apoptotic death altered lung mechanics
CL, RL and IC in KDITSN mice were evaluated with Flexivent
at 72 h, 10 and 24d after siRNAITSN treatment. As expected,
based on extensive ECs apoptosis and pulmonary edema
recorded at 72 h post-siRNAITSN treatment, CL was
decreased by comparison to wild-type mice, when the mean
values where compared. (Fig. 6C, c1); IC was not signifi-
cantly modified (Fig. 6C, c2). At the same time point we
found increase in RL (Fig. 6C, c3), most likely due to
increased pulmonary recoil, an expected effect of lung fluid
accumulation. Interestingly however, at 10d post-siRNAITSN
treatment, the pulmonary function of KDITSN mice evolved
toward increased CL, increased IC and low airway RL,
compared to the wild-type or 72 h post-siRNA mouse lungs.
This observation is consistent with the significant and per-
sistent alveolar destruction, enlargement of the air space and
increased MLI values. Given the ongoing compensatory cell
proliferation, however, the state of endothelium ameliorates
and the vascular leakage leading to accumulation of fluid
within the interstitial space decreases, as already docu-
mented by us [19], fact that may account for CL values at this
time point. In keeping with this observation, 24d post-siR-
NAITSN delivery, pulmonary function of KDITSN mice show
no notable differences compared to controls.
KDITSN mice present increased pulmonary microvessel
density and altered Smad activity
Next, to get insight into the nature of endothelial remodeling
caused by KDITSN we applied GS-1staining, a lectin whose
binding is limited to the glycoproteins of the lung micro-
vasculature (\ 20 lm diameter), [35]. Fluorescent micros-
copy analysis showed in controls strong GS-1 labeling of
Fig. 5 Mouse lung chronically depleted of ITSN-1s show phenotyp-
ically-altered ECs. A BrdU/FITC Ab immunostaining (a1, a4, a5),
followed by CD31/AlexaFluor594 (a2, a6, a7) shows BrdU positive
ECs within alveolar wall, at 10d (a3, arrows) and 24d (a8, a9,
arrows). Arrowheads (a8, a9) point towards BrdU positive alveolar
epithelial cells. Bars: 20 lm, (a1–a9). B Representative Western blots
of lung lysates of control, wt-mice (a), siRNActrl (b) and veh (c),
72 h post-injection as well as siRNAITSN-treated mice, at the time
points indicated, using phospho-specific Erk1/2MAPK and total Erk1/
2MAPK Abs. The graph shows densitometric analysis of Erk1/2MAPK
activation (phospho-Erk1/2 relative to total Erk1/2) as mean ± SEM
of 3 separate experiments. C Expression TGFb, BMP-2/4 and
VEGF-A, in mouse lung lysates of control and siRNAITSN-treated
mice, at the time points indicated assessed by Western blot with
specific anti-TGFb, BMP-2/4 and VEGF-A Abs. Actin was used as
loading control. D. Densitometric analysis of TGF-b, BMP-2/4 and
VEGF-A immunoreactivity. Different Abs and detection conditions
did not allow a quantitative assessment of the ratio between the
growth factors. E. Evaluation of Bad phosphorylation by Western
blotting with anti-phospho Ser112-Bad, Ser136-Bad and Ser155-Bad
Abs. The blots were stripped and reprobed with an anti-Bad Ab. The
Western blots C, E are representative for 3–4 different experiments;
densitometric analyses B, D were applied on 3 different HyBlot CL
films. Densitometric values ± SEM are representative for 3 indepen-
dent experiments
b
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murine lung microvessels and frequent alveolar microves-
sels profiles (Fig. 7A, a1), consistent with well-vascularized
alveolar walls and extensive capillary network. At 10d of
KDITSN, GS-1staining was however, weaker and less
microvessel profiles were detected within the alveolar wall,
consistent with endothelial damage and microvessel loss
(Fig. 7A, a2). While the weaker staining may be caused also
by technical problems such as accessibility of lectin binding
sites within the sections, we believe that this is not the case
since similar extent of lack of uniform labeling was noticed
throughout the survey of siRNAITSN-treated mice, but not in





































































Fig. 6 KDITSN-1s induces mouse lung injury and alters pulmonary
function tests. A Histology (H&E) of untreated (a1), siRNAITSN, 10d,
(a2) and siRNAITSN, 24d, (a3) Bar 20 lm. B Morphometric analyses
of MLI show no difference between the mice with chronic siRNAITSN
(24d) and controls. 30 random high power fields were counted for
each group. Data are shown as mean values ± SEM. *P \ 0.05
(siRNAITSN 24d compared to siRNAITSN, 10d). C Pulmonary function
tests—CL, IC and airway RL—measurements in KDITSN mouse. Lines
within the boxes show medians; bounds of the boxes show 25th and
the 75th percentiles of the data, respectively; the dark circles show
outliers. All data are presented as mean ± SEM; P \ 0.001. Results
are representative for three different experiments, with 3–4 mice/
experimental condition
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of uniformity in the GS-1s staining may be due to the degree
of KDITSN in different areas of murine lung microvascular
bed. In contrast, after 24d of KDITSN the density of lung
alveolar microvessels was increased in comparison not only
to 10d KDITSN but also to wild-type mice (Fig. 7A, a3),
suggesting that prolonged KDITSN triggered microvascu-
lar remodeling, characterized by increased number of cap-
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Fig. 7 Chronic KDITSN-1s in mouse lungs induces microvascular
remodeling A. Micrographs of GS-1 lectin staining of paraffin-
embedded sections show microvessel profiles (arrows), within the
alveolar walls in control (a1), in mice treated with siRNAITSN for 3d
(a2) and in mice treated with siRNAITSN for 24d (a3). Bar 10 lm.
B Ultrastructural features of microvascular remodeling in KDITSN
mouse lungs. Two vessels profiles in wt-mouse lung display elongated
ECs nuclei (b1). Note the relatively uniform thickness of the ECs
throughout the vessel perimeter. Segment of a mid-sized vessel in
KDITSN mouse lung shows a distorted endothelium and several nuclei
protruding into the lumen (b2, arrows). New pulmonary microvessels
(dashed arrows) with narrow openings are abundant and located in
very close proximity to each other. C Smad1/5/8 phosphorylation in
mouse lung cytosolic (light grey bars) and nuclear fractions (dark
grey bars) of controls and siRNAITSN-treated mice. Nuclei were
isolated from mouse lungs as in [69] and extracts were prepared using
NE-PER Nuclear Extraction Reagent (Pierce Biotechnology, Rock-
ford IL). Actin and histone 3 were used as loading controls for the
cytosolic and nuclear fractions respectively. D Smad2 (light grey
bars) and Smad3 (dark grey bars) phosphorylation in total lung lysates
of control and siRNAITSN-treated mice. Total Smad2/3 were used as
loading controls. Results are representative for 3–5 different
experiments
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indicated that the mean number of lung microvessels per
30,000 lm2 surface area in chronic inhibition mice, at 24d
reaches 443 ± 7.1, * 20 % higher than control levels
(365 ± 9). Evidence of EC proliferation and microvascular
remodeling was further obtained by EM morphological
analyses of KDITSN mouse lungs, (Fig. 7B). While under
control conditions, ECs lining the mouse lung vessels show a
relatively uniform diameter/thickness and typical, elongated
nuclei (Fig. 7B, b1), in KDITSN specimens we have detected
vessels profiles where ECs were distorted, varied in their
thickness and displayed several EC nuclei protruding into the
lumen, suggestive of endothelial hyper-proliferation occur-
ring at this level (Fig. 7B, b2). Luminaly bulging ECs nuclei
is a structural feature of forming and developing blood
capillaries, previously documented in other tissues and sys-
tems (Manzke, E., 2005). Note also the underlying area rich
in growing vessels (Fig. 7B, b2, dashed arrows) with small,
narrow lumina and very close to each other, suggestive of an
ongoing remodeling process.
Downstream of TGFb and BMP-2/4 signaling are Smad
proteins, involved in ECs proliferation and angiogenesis
[46]. First, Smad1/5/8 activity was evaluated by Western
blot analyses of both cytosol and nuclear fractions prepared
from lung tissue of control and KDITSN mice at 3, 10, 15
and 24d post-siRNAITSN delivery, using a phospho-Smad1/
5/8 Ab, (Fig. 7C). Phosphorylation of Smad1/5/8/, down-
stream events of both ALK1, a TbR1 whose expression is
restricted to ECs, and BMPR2 [46] was slightly increased
in both fractions at 72 h post-siRNAITSN treatment; then a
gradual decrease, about 30 % lower compared to controls
and 72 h post-siRNAITSN, was detected. Since previous
reports demonstrated that TbR1 signaling is not directly
affected by impaired endocytosis [54], and that inhibition
of BMPR2 endocytosis does not affect Smad1/5/8 phos-
phorylation, but affects their nuclear translocation [55], it is
likely that in a cellular environment deficient in caveolae
and CCVs endocytosis, the BMPR2 endocytic traffic is
altered due to upregulation of compensatory alternative
endocytic pathways, [19]. Both Smad1/5/8 phosphorylation
and nuclear translocation still occur, but less efficiently
compared to controls. At 72 h post-siRNAITSN, the alter-
native endocytic pathways do not function efficiently
enough (Predescu, 2012) to affect BMPR2 endocytic
internalization; the receptor is still on cell surface and less
internalized due to caveolae and CCVs impaired endocy-
tosis, and thus its signaling may be enhanced, resulting in
increased Smad1/5/8 phosphorylation and nuclear translo-
cation, at this time point.
Moreover, the Smad2/3, downstream of TbR1 show
decreased levels of phosphorylation, Fig. 7D. The levels of
Smad2/3 are unchanged, suggesting that Smad2 and Smad3
are not targeted for degradation. It appears that the typical
TbR1/ALK5 signaling has been shifted from the Smad2/3
activation toward a less common Ras/Erk1/2MAPK path-
way, with protective effects on ECs and lung vasculature.
Significantly, as already reported, Smad2/3 inhibition is
consistent with the ECs proliferation [46].
To rule out a possible involvement of Smad 4 and
inhibitory Smad 7 in the inhibition of Smad2/3 activity, we
analyzed by Western blot the expression of the two Smad
proteins in mouse lung lysates (Online Resource 1). No
changes in the expression of the common Smad 4 were
detected. The levels of the inhibitory Smad7, display a
gradual decrease, reaching a 30 % decrease at 24d post-
siRNAITSN delivery compared to Smad7 in the lung lysates
of wt-mice. The observations further support the concept
that the impaired endocytic traffic of TbR1 and activation
of Erk1/2MAPK account for Smad2/3 inhibition.
Since Erk1/2-dependent, Smad2/3-independent TGFb
signaling has been related to collagen production [56, 57],
we further address the lung remodeling and try to elucidate
the mechanism behind the reduction in CL in KDITSN mice
(24d). To this intent, we evaluated the status of extracel-
lular matrix deposition, with focus on collagen. Chronic
ITSN-1s deficiency leads to collagen depositions at the
level of subpleural space (Fig. 8B), in the alveolar septa
(Fig. 8C) as well as in the perivascular spaces (Fig. 8D).
Short septal walls remnants were often noticed with col-
lagen bundles at the tip (Fig. 8C, arrows). EM studies
further indicate that collagen fibrils (F, arrows), and fibrilar
material (proteoglycans, elastic fibers, etc.), accumulated in
the basement membrane between the ECs, smooth muscle
cells and fibroblasts. We estimated that on 23,250 lm2,
(the average surface of selected area), the percentage area
occupied by collagen represents only 3.26 ± 0.14 % in
controls, while in chronic KDITSN mice, (24d), reaches
6.71 ± 0.31 %, Fig. 8H.
Discussion
In this study we evaluated the in vivo effects of ITSN-1s
deficiency on pulmonary ECs apoptosis and lung homeo-
stasis using a KDITSN mouse model in which ITSN-1s was
efficiently and specifically inhibited for 24 consecutive
days, via i.v. delivery of siRNAITSN/cationic liposomes.
Acute KDITSN and loss of Erk1/2
MAPK survival signaling
caused significant ECs apoptosis leading to endothelial
damage, microvessels loss and alveolar destruction. These
results are in keeping with our previous studies showing
that ITSN-1s deficiency interferes with ECs function and
survival by inhibition of MEK/Erk1/2 phosphorylation [8].
Increased ECs death as revealed by TUNEL and caspase-3
activation began at 3d and peaked at 10d of KDITSN. As a
consequence, lung injury occurred rapidly, allowing us for
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a detailed time course analysis of structural destruction and
disease progression.
Studies have shown that in the lungs of chronically
hypoxic rats treated with the VEGFR-2 inhibitor SU5416,
pulmonary ECs death preceded development of severe
PAH, associated with precapillary arterial occlusion by
proliferating ECs [14]. Mouse lung ECs death, as caused
by KDITSN, was a prerequisite for the following ECs pro-
liferation, repair and remodeling process. Within days,
these normally quiescent cells with a low turnover rate,
began to hyper-proliferate, indicating that the survival
signaling, lost due to KDITSN, was re-established.
Expression of TGFb a cytokine that regulates diverse
and often contradictory functions, in a milieu- and cell
type-dependent manner, [46] was increased. In a cellular
environment deficient in Erk1/2 activity and with altered
endocytic trafficking [19] caused by ITSN-1s deficiency,
the typical TbR1/ALK5 signaling has been shifted from
Smad2/3 activation toward a less common Ras/Erk1/2MAPK
pathway, with protective effects on ECs and lung vascu-
lature. The mechanisms underlying TGFb/ALK5-depen-
dent Ras/Erk1/2 activation is an unresolved issue of
considerable interest due to its established role in providing
a growth advantage [58]. TGFb induces Ras/Erk signaling
through direct phosphorylation of the adaptor protein
SchA, [59] leading to its association with Son of Sevenless
(Sos), a Ras GTP/GDP exchange factor, and the growth
factor receptor bound protein 2 [60]. Notably, ITSN-1s
associates with Sos in a protein complex that excludes























Fig. 8 Chronic ITSN-1s deficiency leads to dense perivascular
collagen depositions Representative micrographs of Picrosirius Red-
stained lung sections of control (A) and siRNAITSN-treated mice for
24d (B–D), to assess collagen deposition. Short septal walls remnants
were often noticed with collagen bundles at the tip (C, arrows). Bars
20 lm. Electron micrographs show segments of the alveolar septal
wall in a control microvessel (E), as well as in a postcapillary venule
(10–15 lm diameter) (F), and a precapillary arteriole (20–25 lm
diameter) (G) of ITSN-1s deficient mice. Collagen fibrils (G, arrows),
and fibrilar material (proteoglicans, elastic fibers, etc.), accumulated
in the basement membrane between the ECs, smc and fibroblast. j1—
interendothelial junction, j2—epithelial junction, EC—endothelial
cell, pvs—perivascular space, smc—smooth muscle cell. Bar 500 nm.
H Quantification of the amount of collagen encircling middle-sized
lung vessels in control and ITSN-1s chronic inhibition mice. Results
are representative for 3 different experiments, with 3 mice/experi-
mental condition. Collagen layers were measured in 20–25 randomly
chosen high power fields comprising 25 medium-sized blood vessels
for each experimental condition. Data are expressed as mean ± SEM,
*P \ 0.05
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Sos availability for Grb2 interaction, and thus, preferential
formation of ALK5/Sos/Grb2 signaling complex. This may
result in ineffective assembly of ALK5/Smad2/SARA
complexes and subsequent alteration of the Smad2/3-Erk1/2
signaling balance toward persistent Ras/MEK/Erk1/2 acti-
vation. In addition, while Smad1/5 phosphorylation, down-
stream of BMPR2 occurs at the plasma membrane and is not
affected by deficient endocytic trafficking, continuation of
Smad signaling requires receptor internalization [55], which
cannot occur efficiently due to impaired endocytic traffic
caused by KDITSN [2, 19]. Apparently, the endocytic dys-
function and loss of ITSN-1s-mediated Erk1/2MAPK activa-
tion, directed Smad1/5/8 activity, downstream of BMPR2
and ALK1, to avoid excessive ECs proliferation, while
facilitating ECs proliferation and the recovery of vessel loss
(Fig. 9). Moreover, despite the TbR1/ALK5 ability to signal
without endocytic internalization, events such as Smad1/5/8
and Ras/Erk1/2MAPK activation may have an inhibitory
effect on Smad2/3 pathway in lung ECs impaired in endo-
cytic trafficking [61].
Sustained activation of Erk1/2 is necessary for cells
progressing from G1 to S-phase and it is usually associated
with induction of D-type cyclins and assembly with their
catalytic partners that phosphorylate the retinoblastoma
proteins resulting in release of E2F and transcription of
genes required for DNA replication [10]. Thus, Erk1/
2-Smad2/3 signaling switch may affect two well-known
molecular mechanisms of cell growth arrest by TGFb in
the G1-phase of cell cycle, (i) downregulation of D type
cyclins and cyclin-dependent kinases expression [62–64]
and (ii) activation of cyclin-dependent kinases inhibitors
[65], events that may account for initiation of the ECs
hyper-proliferative phenotype.
Bad phosphorylation by growth factors activated Erk1/
2MAPK, and inactivation of its pro-apoptotic properties,
already demonstrated in cultured neurons and in models of
cerebral ischemia, [66] may be part of the molecular
mechanism leading to the EC apoptotic-resistant phenotype
caused by chronic KDITSN and lung repair.
Although the crosstalk between the TGFb and other
signaling pathways was not addressed in detail in these
experimental settings, the studies described here demon-
strate that Erk1/2MAPK activation, Bad phosphorylation and
the perturbed Smad signaling downstream of ALK5 and
BMPR2, play an important role in lung ECs survival and
injury repair.
Vascular remodeling induced by chronic KDITSN was
assessed by a detailed survey of AQP-1 and GS-1 lectin
labeling, widely used to visualize the mouse lung micro-
vessels [35]. Excessive apoptotic ECs death recorded at
72 h and 10d post-siRNA treatment, and the decrease of
microvessels density were followed by ECs proliferation
and microvascular repair/development process that not
only restored the number of lung microvessels, but appar-
ently, added new microvessels to the system. Increased
expression of both VEGF-A, a central growth and survival
factor for the ECs [50] and BMP2/4 already implicated in
capillary sprouting via Erk1/2MAPK signaling [49], may be,
at least partly responsible for this KDITSN mouse pheno-
type. Moreover, the apoptotic/proliferative ECs coexis-
tence (high cellular death/growth) in the murine lung
endothelium at 10d of KDITSN indicates the conversion
time of normal, surviving ECs to a hyper-proliferative
phenotype. What initiated out of necessity for tissue
replenishment, progresses to microvascular remodeling due
to a newly acquired hyper-proliferative ECs phenotype. As
shown KDITSN in the mouse lungs also affected lung epi-

















































Fig. 9 Schematic representation of TGFb-Smads/Erk1/2MAPK sig-
naling switch in ECs of KDITSN TGFb transmits its signal by binding
to type II and type I receptors, resulting in activation of type I receptor
and subsequent phosphorylation of R-Smads. ITSN-1s binds mSos [7]
and thus, KDITSN may increase mSos availability for Grb2 interaction,
and preferential formation of ALK5/mSos/Grb2 signaling complex.
This may result in ineffective assembly of ALK5/Smad2/SARA
complexes and subsequent alteration of the Smad2/3-Erk1/2 signaling
balance toward persistent Ras/MEK/Erk1/2 activation. ALK5 func-
tions to activate Ras/Erk1/2MAPK necessary for restoring pro-survival
signaling, lost due to KDITSN. This signaling event may suppress
Smad2/3 phosphorylation. Note that Smad2/3 phosphorylation can be
inhibited not only upon Ras/Erk1/2 activation but also upon Smad1/5/
8 activation. Smad1/5/8 phosphorylation downstream of BMPR2 is
triggered while the receptor is at the plasma membrane; the
transcriptional response is however, dependent on BMPR2 internal-
ization [55]
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siRNA effect on lung epithelium may account for the
observed epithelial cells apoptotic death. Lung parenchy-
mal proliferation might be expected as a result of increased
number of blood vessels, providing the energy substrate for
accelerated alveolar replenishment [67]. Thus, it is not
surprising that BrdU staining of lungs sections with chronic
KDITSN revealed also a multitude of proliferative epithelial
cells. At the end of the study no significant difference was
found between MLI of these specimens and controls. Even
if the MLI shows overall equality, lung morphology after
24d of ITSN-1s suppression did not resemble controls. Few
increased airspace regions were in complementary distri-
bution to various areas with closely packed alveoli, smaller
in size than in controls. This data suggest that hyper-pro-
liferative pulmonary ECs prompted pneumocytes prolifer-
ation, reactive to the favorable milieu created by the
vascular development. While the role of epithelial cell
apoptosis in lung repair and remodeling cannot be disre-
garded, given the efficient and specific delivery of siR-
NAITSN/cationic liposomes to pulmonary ECs and the high
endothelial content of the lung tissue [30], the findings
reported here are highly relevant for ECs of the lung.
During the 24d of ITSN-1s deficiency, pulmonary func-
tion of KDITSN mice evolved from low CL and increased RL
at 72 h post-siRNA delivery, toward increased CL and
decreased RL at 10d, while, at the end of the study both
parameters were close to control values. Compensatory
proliferation, observed at 10d post-siRNA treatment, con-
tributed to the amelioration of endothelial injury and reduced
the pulmonary fluid buildup, events that are behind the
change in pulmonary mechanics at 10d. Depositions of
matrix components (collagen and elastin fibers) and increase
in interstitial cell population were commonly seen at the
ultrastructural level in mouse lung vessels with chronic
KDITSN. The remodeling of the alveolo-capillary functional
unit (i.e. epithelial cells proliferation, collagen deposition
within alveolar septum, increased microvessels density)
further improved the CL, RL and IC of the injured lungs.
Taken together, our data showed that in the pulmonary
tissues of mice deficient of ITSN-1s, impaired endocytic
membrane traffic and initial ECs apoptosis was followed
by ECs phenotypic changes toward hyper-proliferation and
apoptosis-resistance against ITSN-1s deficiency as well as
microvascular remodeling in the remaining pulmonary
microvascular bed. Interestingly, TbR1 downstream sig-
naling was apparently switched from the canonical Smad2/
Smad3 toward Erk1/2MAPK. This signaling switch proved
to be central for ECs survival, maintaining vascular
integrity and lung homeostasis.
The findings are relevant considering that ITSN-1s is a
general endocytic protein, a regulator of mitochondrial
apoptosis and a GrB substrate [15]. Under inflammatory
conditions and increased GrB levels, loss of full-length
ITSN-1s may cause endocytic dysfunction, loss of pro-
survival signaling and apoptotic ECs death. As result, loss
of blood vessels, damage of the alveolar wall, abnormal or
incomplete tissue repair may occur. These events are major
determinants able to cause during disease progression the
selection of hyper-proliferative and apoptotic-resistant cell
phenotypes [68]. The findings implicate ITSN-1s, a key
endocytic and pro-survival protein of lung endothelium,
and the biological processes regulated by it (i.e., endocy-
tosis, transcytosis, cell survival and apoptosis) in vascular
remodeling and pathology of lung disorders.
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